Chimerix Investor Conference Presentation Deck

✓ Pediatric Case Study 8-year-old thalamic H3.3 K27M DMG initially diagnosed in May 2018 First-line therapy: radiation, dasatinib, everolimus and bevacizumab Second-line therapy: 375mg weekly ONC201 monotherapy initiated Apr 2019 following progression on first-line therapy Clinical and radiographic improvement over >2 years of therapy PS: absolute value Tumor size: % change from baseline 28 100 80 60 40 20 0 0 3 6 וכ T 12 Months from First Dose 15 Performance Status (PS) Tumor Size T 18 21 24 Pre-ONC201 baseline 9 months on ONC201 18 months on ONC201 O 2021 Chimerix, Inc

View entire presentation